PolyPeptide Group AG (PPGN) - Net Assets
Based on the latest financial reports, PolyPeptide Group AG (PPGN) has net assets worth CHF330.99 Million CHF (≈ $418.45 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF773.07 Million ≈ $977.37 Million USD) and total liabilities (CHF442.08 Million ≈ $558.91 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PolyPeptide Group AG (PPGN) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF330.99 Million |
| % of Total Assets | 42.81% |
| Annual Growth Rate | 15.86% |
| 5-Year Change | 101.08% |
| 10-Year Change | N/A |
| Growth Volatility | 51.55 |
PolyPeptide Group AG - Net Assets Trend (2018–2024)
This chart illustrates how PolyPeptide Group AG's net assets have evolved over time, based on quarterly financial data. Also explore PPGN total asset value for the complete picture of this company's asset base.
Annual Net Assets for PolyPeptide Group AG (2018–2024)
The table below shows the annual net assets of PolyPeptide Group AG from 2018 to 2024. For live valuation and market cap data, see PPGN market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CHF357.24 Million ≈ $451.65 Million |
-6.29% |
| 2023-12-31 | CHF381.23 Million ≈ $481.97 Million |
-9.59% |
| 2022-12-31 | CHF421.68 Million ≈ $533.11 Million |
+0.12% |
| 2021-12-31 | CHF421.17 Million ≈ $532.48 Million |
+137.07% |
| 2020-12-31 | CHF177.66 Million ≈ $224.61 Million |
+18.90% |
| 2019-12-31 | CHF149.42 Million ≈ $188.90 Million |
+1.18% |
| 2018-12-31 | CHF147.67 Million ≈ $186.70 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PolyPeptide Group AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 43.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CHF140.48 Million | 39.32% |
| Common Stock | CHF302.00K | 0.08% |
| Other Components | CHF216.47 Million | 60.59% |
| Total Equity | CHF357.24 Million | 100.00% |
PolyPeptide Group AG Competitors by Market Cap
The table below lists competitors of PolyPeptide Group AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PennantPark Floating Rate Capital Ltd
NYSE:PFLT
|
$810.61 Million |
|
Hainan Haiyao Co Ltd
SHE:000566
|
$810.64 Million |
|
Formosa Taffeta Co Ltd
TW:1434
|
$811.01 Million |
|
Root Inc
NASDAQ:ROOT
|
$811.06 Million |
|
Molinos Agro SA
BA:MOLA
|
$809.94 Million |
|
DL Holdings CO. LTD.
KO:000210
|
$809.93 Million |
|
Gansu Guofang Gongmao(Grp)
SHG:601086
|
$809.87 Million |
|
Tianjin Economic-technological Development Area Co Ltd
SHE:000652
|
$809.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PolyPeptide Group AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 381,225,000 to 357,244,000, a change of -23,981,000 (-6.3%).
- Net loss of 19,564,000 reduced equity.
- Other comprehensive income decreased equity by 23,049,000.
- Other factors increased equity by 18,632,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF-19.56 Million | -5.48% |
| Other Comprehensive Income | CHF-23.05 Million | -6.45% |
| Other Changes | CHF18.63 Million | +5.22% |
| Total Change | CHF- | -6.29% |
Book Value vs Market Value Analysis
This analysis compares PolyPeptide Group AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.55x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7.81x to 3.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | CHF4.92 | CHF38.45 | x |
| 2019-12-31 | CHF1.25 | CHF38.45 | x |
| 2020-12-31 | CHF5.92 | CHF38.45 | x |
| 2021-12-31 | CHF13.11 | CHF38.45 | x |
| 2022-12-31 | CHF12.78 | CHF38.45 | x |
| 2023-12-31 | CHF11.56 | CHF38.45 | x |
| 2024-12-31 | CHF10.83 | CHF38.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PolyPeptide Group AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.78%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 2.12x
- Recent ROE (-5.48%) is below the historical average (13.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 16.13% | 13.26% | 0.63x | 1.92x | CHF9.05 Million |
| 2019 | 68.90% | 12.70% | 0.66x | 8.17x | CHF22.00 Million |
| 2020 | 17.64% | 13.97% | 0.60x | 2.12x | CHF13.57 Million |
| 2021 | 11.22% | 16.75% | 0.47x | 1.41x | CHF5.14 Million |
| 2022 | 1.84% | 2.76% | 0.49x | 1.37x | CHF-34.40 Million |
| 2023 | -13.49% | -16.06% | 0.46x | 1.81x | CHF-89.56 Million |
| 2024 | -5.48% | -5.78% | 0.45x | 2.12x | CHF-55.29 Million |
Industry Comparison
This section compares PolyPeptide Group AG's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,835,699,156
- Average return on equity (ROE) among peers: -4.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PolyPeptide Group AG (PPGN) | CHF330.99 Million | 16.13% | 1.34x | $810.06 Million |
| CURATIS N AG (CURN) | $55.33 Million | -27.15% | 0.25x | $89.64 Million |
| Galderma Group N (GALD) | $4.14 Billion | -3.40% | 1.76x | $37.01 Billion |
| Sandoz Group AG (SDZ) | $6.83 Billion | 5.99% | 1.32x | $28.94 Billion |
| Siegfried Holding Ltd (SFZN) | $316.35 Million | 6.60% | 0.51x | $3.71 Billion |
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including t… Read more